Navigation Links
Free Prostate Screenings Offered at Virginia G. Piper Cancer Center
Date:9/2/2010

SCOTTSDALE, Ariz., Sept. 2 /PRNewswire-USNewswire/ -- Recognizing that early detection can save lives, the Virginia G. Piper Cancer Center at Scottsdale Healthcare is offering free prostate cancer screenings from 8:30 a.m.-12 p.m. on Saturday, Sept. 11.

Urologists from Scottsdale Healthcare will be available to answer questions and talk about prostate cancer diagnosis and treatment options. Free prostate screenings include a Prostate Specific Antigen blood test and digital rectal exam.

The Virginia G. Piper Cancer Center at Scottsdale Healthcare is located at 10460 N. 92nd St. on the campus of Scottsdale Healthcare Shea Medical Center.

Appointments for the screening can be made by calling 480-882-4636.

  • Hear about prostate cancer diagnosis and treatment options at 8:30 a.m. and 10:45 a.m.
  • See nutrition and cooking demonstrations for prostate health at 9:30 a.m. and 10:30 a.m.
  • Adult flu shots will be available for $25.
  • Get 25% off at Tina's Treasures Boutique, dedicated to meeting the needs of cancer patients.

Attendees can take the controls of a daVinci robotic surgical system to experience the precision it offers in minimally invasive surgery. Arizona's first daVinci robot-assisted prostatectomy was performed by surgeons at Scottsdale Healthcare.

The daVinci is the world's leading surgical robot for minimally invasive procedures, which result in smaller incisions, less post-operative pain and faster recovery times. Scottsdale Healthcare has the longest experience with the daVinci robot of any Arizona hospital, acquiring the state's first daVinci in 2001.

Surgeons are now using three of the high-tech daVinci robots at Scottsdale Healthcare Thompson Peak Hospital and Scottsdale Healthcare Shea Medical Center. One of Scottsdale Healthcare's experienced daVinci surgeons will be on hand to answer questions about robotic surgery.

According to the American Cancer Society:

  • 1 in 6 men is at a lifetime risk of prostate cancer.
  • About 1 man in 36 will die of prostate cancer.
  • Almost 2 out of 3 prostate cancers are found in men over age 65.
  • Prostate cancer is the second leading cause of cancer death in American men.
  • Other than skin cancer, prostate cancer is the most common cancer in American men.

The Virginia G. Piper Cancer Center at Scottsdale Healthcare opened in 2001 as the first major cancer center in greater Phoenix, offering comprehensive cancer research, diagnosis, treatment, prevention and support services in a single location. The Commission on Cancer of the American College of Surgeons has awarded Accreditation with Commendation to the Scottsdale Healthcare cancer program.

Scottsdale Healthcare is the community-based, not-for-profit parent organization of the Scottsdale Healthcare Osborn Medical Center, Scottsdale Healthcare Shea Medical Center and Scottsdale Healthcare Thompson Peak Hospital, Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale Healthcare Research Institute and Scottsdale Healthcare Foundation. A leader in medical innovation, talent and technology, Scottsdale Healthcare was founded in 1962 and is based in Scottsdale, Ariz. For more information, visit www.shc.org.


'/>"/>
SOURCE Scottsdale Healthcare
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
2. Use it or Lose it: A New Theory About Preserving Erectile Function After Prostate Surgery
3. Gene Fusion Subtypes in Prostate Carcinoma Have Clinical Implications
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
6. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
7. Study Suggests Soy Protein May Reduce Prostate Cancer Risk
8. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
9. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
10. Prostate Cancer Treatment Centre Receives Funding for Clinical Trials
11. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... on the development of oral drug delivery systems, announced ... has agreed to schedule an End-of-Phase II meeting with ... its oral insulin capsule ORMD-0801 in the treatment of ... and secondary endpoints by indicating a statistically significant lowering ...
(Date:7/10/2017)... -- The tenth annual BioPharm America™ will take ... the Sheraton Boston Hotel, September 26–27. The event will ... makers and innovative biotech startup companies. The event is ... impactful days. BioPharm America is now part of Biotech ... with 4,500+ life science industry influencers participating in 8+ ...
(Date:7/5/2017)... 5, 2017 Oramed Pharmaceuticals Inc. ... ), a clinical-stage pharmaceutical company focused on the development ... received approval from the Israel Securities Authority to dual-list its ... common stock will commence trading on the TASE on July ... market capitalization of the Company, it is expected that Oramed ...
Breaking Medicine Technology:
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... ... in Oakland, California effectively destroyed the construction site and threatened numerous homes and ... July 7th article on NBCLosAngeles.com. Los Angeles Area consulting firm Fire ...
(Date:7/24/2017)... ... ... The International Essential Tremor Foundation (IETF) will host a free educational forum ... will take place on Saturday, Aug. 26 at the Embassy Suites by Hilton Cleveland ... 9 a.m. to 12 p.m., with check-in beginning at 8 a.m. The event is ...
(Date:7/24/2017)... ... ... Axiad IDS , a leading provider of trusted identities for enterprise, ... to expand its solution to help government contractors more quickly and cost-effectively comply with ... address the authentication requirements within NIST SP800-171, but no matter how you address ...
(Date:7/24/2017)... ... July 24, 2017 , ... Independence Blue Cross (Independence) ... an Innovation Collaboration program, have signed a five-year agreement that will marshal resources ... care members and patients receive. The agreement also signifies Jefferson Health officially joining ...
(Date:7/24/2017)... ... July 24, 2017 , ... Puregraft, the ... announces the issuance of United States Patent Number 9,695,398 (the '398 patent) and ... The '398 and '324 patents cover methods and systems for optimizing fat ...
Breaking Medicine News(10 mins):